Search research articles
Contact Us
Filters
Showing results (1-10 of 44) with videos related to
Page
of 5
Sort By:
The Lancet. Oncology
|
May 3, 2019
Early use of abiraterone and radium-223 in metastatic prostate cancer
Elif Hindié, Clément Morgat
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
January 2, 2025
Gastrin-Releasing Peptide Receptor Imaging and Therapy in the Era of Personalized Medicine
Clément Morgat, Andrei Iagaru, Elif Hindié
European Urology
|
April 21, 2024
Re: Renu S. Eapen, James P. Buteau, Price Jackson, et al. Administering [<sup>177</sup>Lu]Lu-PSMA-617 Prior to Radical Prostatectomy in Men with High-risk Localised Prostate Cancer (LuTectomy): A Single-centre, Single-arm, Phase 1/2 Study. Eur Urol. 2024;85:217-226
Elif Hindié, Christophe Champion, Clément Morgat
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
August 19, 2017
Somatostatin Antagonists for Radioligand Therapy of Nonendocrine Tumors
Elif Hindié, Paolo Zanotti-Fregonara, Clément Morgat
The Lancet. Oncology
|
June 29, 2026
Terbium-161 might be superior to lutetium-177 for oligometastases
Elif Hindié, Alexandre Larouze, Clément Morgat, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
March 12, 2017
Predicting the outcome of peptide receptor radionuclide therapy in neuroendocrine tumors: the importance of dual-tracer imaging
Paolo Zanotti-Fregonara, Clément Morgat, Christophe Champion, et al.
Seminars in Nuclear Medicine
|
August 12, 2025
GRPR Expression in Metastatic Cancers: A Review of Potential Application of GRPR-Radioligand Therapy
Aurélien Callaud, Heying Duan, Elif Hindié, et al.
Lancet (London, England)
|
August 8, 2021
Targeted radioactive therapy for prostate cancer
Elif Hindié, Clément Morgat, Mario E Alcocer-Ávila, et al.
EJNMMI Physics
|
November 21, 2024
Comparative analysis of positron emitters for theranostic applications based on small bioconjugates highlighting <sup>43</sup>Sc, <sup>61</sup>Cu and <sup>45</sup>Ti
Elif Hindié, Ulli Köster, Christophe Champion, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
June 15, 2023
Membrane and Nuclear Absorbed Doses from <sup>177</sup>Lu and <sup>161</sup>Tb in Tumor Clusters: Effect of Cellular Heterogeneity and Potential Benefit of Dual Targeting-A Monte Carlo Study
Alexandre Larouze, Mario Alcocer-Ávila, Clément Morgat, et al.
Page
of 5
Search research articles
Search
Showing results (1-10 of 44) with videos related to
Sort By:
Page
of 5
The Lancet. Oncology
|
May 3, 2019
Early use of abiraterone and radium-223 in metastatic prostate cancer
Elif Hindié, Clément Morgat
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
January 2, 2025
Gastrin-Releasing Peptide Receptor Imaging and Therapy in the Era of Personalized Medicine
Clément Morgat, Andrei Iagaru, Elif Hindié
European Urology
|
April 21, 2024
Re: Renu S. Eapen, James P. Buteau, Price Jackson, et al. Administering [<sup>177</sup>Lu]Lu-PSMA-617 Prior to Radical Prostatectomy in Men with High-risk Localised Prostate Cancer (LuTectomy): A Single-centre, Single-arm, Phase 1/2 Study. Eur Urol. 2024;85:217-226
Elif Hindié, Christophe Champion, Clément Morgat
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
August 19, 2017
Somatostatin Antagonists for Radioligand Therapy of Nonendocrine Tumors
Elif Hindié, Paolo Zanotti-Fregonara, Clément Morgat
The Lancet. Oncology
|
June 29, 2026
Terbium-161 might be superior to lutetium-177 for oligometastases
Elif Hindié, Alexandre Larouze, Clément Morgat, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
March 12, 2017
Predicting the outcome of peptide receptor radionuclide therapy in neuroendocrine tumors: the importance of dual-tracer imaging
Paolo Zanotti-Fregonara, Clément Morgat, Christophe Champion, et al.
Seminars in Nuclear Medicine
|
August 12, 2025
GRPR Expression in Metastatic Cancers: A Review of Potential Application of GRPR-Radioligand Therapy
Aurélien Callaud, Heying Duan, Elif Hindié, et al.
Lancet (London, England)
|
August 8, 2021
Targeted radioactive therapy for prostate cancer
Elif Hindié, Clément Morgat, Mario E Alcocer-Ávila, et al.
EJNMMI Physics
|
November 21, 2024
Comparative analysis of positron emitters for theranostic applications based on small bioconjugates highlighting <sup>43</sup>Sc, <sup>61</sup>Cu and <sup>45</sup>Ti
Elif Hindié, Ulli Köster, Christophe Champion, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
June 15, 2023
Membrane and Nuclear Absorbed Doses from <sup>177</sup>Lu and <sup>161</sup>Tb in Tumor Clusters: Effect of Cellular Heterogeneity and Potential Benefit of Dual Targeting-A Monte Carlo Study
Alexandre Larouze, Mario Alcocer-Ávila, Clément Morgat, et al.
Page
of 5